ATTR Stabilizers vs. Silencers: What's the Difference?

When treating ATTR amyloidosis, the main goal is to slow down the disease by preventing a protein called transthyretin (TTR) from misfolding and forming harmful amyloid deposits in your organs ^[1][2]. To do this, specialists primarily rely on two classes of disease-modifying medications: stabilizers and silencers.

The simplest difference between the two is how they interact with the TTR protein: stabilizers act like a molecular “glue” to keep the existing protein intact in your bloodstream, while silencers work in the liver to significantly reduce the amount of TTR protein your body produces ^[2][3]. Neither class of drug cures the disease, permanently alters your DNA, or reliably clears away existing amyloid deposits, but both have been shown to significantly slow disease progression ^[1][4].

Stabilizers: The “Glue” That Holds Proteins Together

Normally, the TTR protein circulates in your blood as a four-part structure called a tetramer ^[2]. In ATTR amyloidosis, this structure becomes unstable, falls apart, misfolds, and clumps together to form amyloid ^[1].

Stabilizers are medications that bind directly to the TTR protein while it is circulating in your blood ^[2]. They act like a molecular glue, locking the four-part structure together so it is much less likely to break apart and misfold ^[1]. Because the protein remains stable, the formation of new amyloid deposits is slowed down ^[1].

Common stabilizers include:

• Tafamidis (Vyndaqel/Vyndamax): A daily oral pill primarily approved and used for ATTR cardiomyopathy (heart involvement) ^[5][6].
• Acoramidis: A newer oral stabilizer also designed to tightly bind the TTR protein, studied and approved in certain regions for cardiomyopathy ^[1][7].

Because stabilizers keep the protein intact rather than destroying it, patients taking these medications may see their blood TTR levels remain stable or even rise ^[8]. However, a rise in TTR is not how doctors measure success. Instead, they monitor your heart and physical function through clinical exams to see if the disease is slowing down ^[9].

Silencers: Reducing Protein Production at the Source

Instead of stabilizing the protein in the bloodstream, silencers target the problem at the source. Most of the body’s TTR protein is manufactured in the liver ^[3]. Silencers use technologies like RNA interference or antisense therapy to intercept the temporary messenger instructions (mRNA) your liver uses to make TTR ^[4][10].

By degrading these instructions, silencers tell the liver to drastically reduce its production of TTR ^[3]. Because they target RNA rather than DNA, they do not permanently alter your genetics, which is why they must be taken repeatedly ^[10]. With much less TTR entering your bloodstream, there is less available to form new amyloid deposits ^[8]. Patients on silencers often see their blood TTR levels drop significantly (sometimes by an average of 80% or more in trials), though individual results vary ^[11][12].

Common silencers include:

• Patisiran (Onpattro): Given as an intravenous (IV) infusion every 3 weeks. It requires pre-medications to prevent infusion-related reactions ^[11].
• Vutrisiran (Amvuttra): Given as an injection under the skin every 3 months (12 weeks) ^[13].
• Eplontersen (Wainua): Given as an injection under the skin every 4 weeks ^[12].
• Inotersen (Tegsedi): An older injection requiring strict, regular blood tests to monitor for serious drops in platelets and kidney issues ^[10].

A Note on Vitamin A: The TTR protein normally helps carry Vitamin A around the body. Because silencers heavily reduce TTR, your Vitamin A levels will drop ^[14]. Patients taking silencers are usually prescribed a specific daily Vitamin A supplement ^[14]. However, Vitamin A can be highly toxic at excessive doses, especially during pregnancy. Never self-treat with high doses to try and “normalize” your blood levels, and always report new visual changes—like night blindness or dry eyes—to your doctor immediately for an eye evaluation ^[14].

How You and Your Doctor Will Choose

There is no definitive evidence showing that one class of drug is universally better than the other, and taking a stabilizer and a silencer at the same time is not routinely recommended due to a lack of evidence proving added benefit ^[1][9][15].

Instead, your specialist will recommend a treatment based on several factors:

• Your Disease Phenotype: Whether your ATTR is primarily affecting your heart (cardiomyopathy) or your nerves (polyneuropathy—causing numbness, weakness, or autonomic issues) heavily influences the choice ^[5][7]. Tafamidis and acoramidis are primarily used for cardiomyopathy ^[7][16]. Patisiran and eplontersen are largely approved for hereditary polyneuropathy ^[5][7]. Vutrisiran has strong evidence and approvals for both polyneuropathy and cardiomyopathy, depending on your region ^[9][7].
• Hereditary vs. Wild-Type: Whether your disease is caused by a genetic variant (hereditary) or is related to aging (wild-type) affects which drugs are approved for your use ^[5][16]. For example, silencers are strongly recommended as a first-line option for hereditary polyneuropathy ^[17].
• Method of Administration & Side Effects: You and your doctor must decide what fits your life and health best—taking a daily pill (stabilizers) versus managing clinic infusions, pre-medications, or regular injections (silencers) ^[13][12][11].
• Local Approvals: Approvals and insurance coverage vary significantly by country and region, which may dictate which therapy you are allowed to start first ^[9][18].

Whichever medication you choose, it is important to begin treatment as early as possible before irreversible organ damage occurs ^[5][19]. It is also important to remember that these medications slow the underlying disease, but they do not replace the need for supportive care—such as managing heart failure symptoms, blood pressure, or neuropathic pain ^[9].